Q-omics provides the consensus-scored C8orf74 profile across patient tissues and cancer cell-line models. C8orf74 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, C8orf74 is differentially expressed in 8, with the highest sampling consensus in COAD. Additionally, C8orf74 RNA expression shows 7,193 significant gene co-expression associations, with the highest sampling consensus in PAAD. Together, these results highlight KIRC, COAD, and PAAD as cancer lineages where C8orf74 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for C8orf74 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes C8orf74 survival associations across molecular data types. C8orf74 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible C8orf74 RNA expression–survival associations across cancer types. High C8orf74 expression shows unfavorable associations in KIRC, UCS, PAAD, MESO and LUAD, but favorable associations in ACC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for C8orf74 RNA expression.
This table summarizes C8orf74 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for C8orf74. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. C8orf74 shows lower tumor expression in HNSC and higher tumor expression in COAD, LUAD, BRCA, PAAD and BLCA. The COAD box plot shows higher C8orf74 RNA expression in tumor versus normal tissue (log2 FC = +0.145, t-test p < 0.001).
This table shows molecular features associated with C8orf74 in patient tissues and cancer cell lines. In patient samples, C8orf74 shows the broadest associations at the RNA and protein expression levels, with PAAD recurring as the lineage with the largest associated feature set. In cancer cell lines, C8orf74 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
